Arthur L. Shaffer

National Institutes of Health — United States

Medicine · Health Sciences

51h-index20.4kcitations132works11.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(47), Chronic Lymphocytic Leukemia Research(46), Immune Cell Function and Interaction(28), T-cell and B-cell Immunology(18), Multiple Myeloma Research and Treatments(12)

Publications132 total

Axes of biological variation in diffuse large B cell lymphoma
Cancer Cell·2026Open Access
Gene-regulatory axes of diffuse large B-cell lymphoma subtypes
Blood·2025Open Access
AZD4512: A novel CD22-directed antibody-drug conjugate for the treatment of b-cell malignancies
Blood·2025
Genetic Subclones Reveal Phenotypic Heterogeneity in Diffuse Large B-Cell Lymphoma
Blood·2024· 1 citedOpen Access
Oral cholera vaccine in cholera prevention and control, Malawi
UNC Libraries·2024· 1 citedOpen Access
Multi-omic profiling of follicular lymphoma reveals changes in tissue architecture and enhanced stromal remodeling in high-risk patients
Cancer Cell·2024· 54 citedOpen Access
Response to Bruton’s tyrosine kinase inhibitors in aggressive lymphomas linked to chronic selective autophagy
Cancer Cell·2024· 22 citedOpen Access
First Disclosure of AZD9829, a TOP1i-ADC Targeting CD123: Promising Preclinical Activity in AML Models with Minimal Effect on Healthy Progenitors
Blood·2023· 5 cited
A Multi-Modal Analysis of Acquired Resistance to Acalabrutinib and Pirtobrutinib Provides Potential Strategies to Augment Treatment Outcome with BTKi Drugs
Blood·2023Open Access
Exceptional Response to BTK Inhibitors in Aggressive Lymphomas Linked to Chronic Selective Autophagy
Blood·2023· 1 citedOpen Access
Supplementary Table 5 from Overcoming Acquired Epigenetic Resistance to BTK Inhibitors
2023Open Access
Supplementary Methods from Overcoming Acquired Epigenetic Resistance to BTK Inhibitors
2023Open Access
Supplementary Table 3 from Overcoming Acquired Epigenetic Resistance to BTK Inhibitors
2023Open Access
Supplementary Table 3 from Overcoming Acquired Epigenetic Resistance to BTK Inhibitors
2023Open Access
Supplementary Table 6 from Overcoming Acquired Epigenetic Resistance to BTK Inhibitors
2023Open Access
Supplementary Table 5 from Overcoming Acquired Epigenetic Resistance to BTK Inhibitors
2023Open Access
Supplementary Table 7 from Overcoming Acquired Epigenetic Resistance to BTK Inhibitors
2023Open Access
Supplementary Figures and Legends from Overcoming Acquired Epigenetic Resistance to BTK Inhibitors
2023Open Access
Data from Overcoming Acquired Epigenetic Resistance to BTK Inhibitors
2023Open Access
Data from Overcoming Acquired Epigenetic Resistance to BTK Inhibitors
2023Open Access
page 1 of 7Next →

Frequent Co-authors

Louis M. Staudt(43), George W. Wright(20), Hong Zhao(16), Yandan Yang(14), Ryan M. Young(13), Wenming Xiao(13), Xin Yu(12), Andreas Rosenwald(12), Weihong Xu(10), Elaine S. Jaffe(10), Elı́as Campo(9), John Powell(9), Michele Ceribelli(9), Da Wei Huang(8), James D. Phelan(8), Wing C. Chan(8), Randy D. Gascoyne(8), German Ott(8), Jan Delabie(8), Lisa M. Rimsza(8)